Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: A systematic review and economic evaluation
The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): A systematic review and economic model
MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS
1498P WHAT IS THE CLINICAL EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENTS FOR THE TREATMENT OF CANCER TREATMENT-INDUCED ANAEMIA?
A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA